AML-197 Clinical Outcomes and Treatment Patterns in Adult Patients With FMS-Like Tyrosine Kinase 3 Internal Tandem Duplication Positive Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the US and Canada: CIBMTR® (Center for International Blood and Marrow Transplant Research Analysis)

Allogeneic hemopoietic cell transplantation (allo-HCT) is commonly used to treat patients with acute myeloid leukemia (AML) with internal tandem duplication of the FMS-like tyrosine kinase 3 gene (FLT3-ITDmut+). However, key characteristics and clinical outcomes are not fully understood. Determine t...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2023-09, Vol.23, p.S276-S276
Main Authors: Burns, Linda J., Pandya, Bhavik J., Chen, Karen, Wang, Tao, Xie, Bin, Touya, Maelys, Spalding, James, Block, Alana, Kuperman, Gaston, Young, Christopher, Muffly, Lori
Format: Article
Language:English
Subjects:
allogeneic hemopoietic cell transplantation
AML
FLT3 inhibitor
leukemia free survival
overall survival
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Allogeneic hemopoietic cell transplantation (allo-HCT) is commonly used to treat patients with acute myeloid leukemia (AML) with internal tandem duplication of the FMS-like tyrosine kinase 3 gene (FLT3-ITDmut+). However, key characteristics and clinical outcomes are not fully understood. Determine the impact of patient, disease, and transplantation characteristics on outcomes, trends in maintenance therapy, and causes of death for patients ≥18 years with FLT3-ITDmut+ AML undergoing first allo-HCT. Observational cohort study of recipients of human leukocyte antigen identical sibling, haploidentical, 8/8 or 7/8 unrelated, or cord blood donor allo-HCT in the USA and Canada between January 1, 2014, and December 31, 2019, reported in the CIBMTR® database. Patients enrolled in NCT02997202 (postallo-HCT gilteritinib maintenance) were excluded. 3 147 patients with disease status at allo-HCT: first complete remission (CR1; n=2389); second or greater complete remission (≥CR2; n=340); and relapsed/refractory (R/R; n=418). Overall survival (OS) and leukemia free survival (LFS) were the main outcomes. Other outcomes included relapse and nonrelapse mortality (NRM). Cox proportional hazards models were used for multivariable analyses. Median (range) follow-up for all patients was 43 (3–90) months. Characteristics were similar for all cohorts. Disease status (≥CR2 vs CR1) significantly impacted OS (hazard ratio [HR] 1.44; 95% confidence interval [CI] 1.20–1.73; P=0.0001]), LFS (HR 1.98; 95% CI 1.52–2.59; P
ISSN:2152-2650
2152-2669
DOI:10.1016/S2152-2650(23)01011-X